首页 | 本学科首页   官方微博 | 高级检索  
     


Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer
Authors:Linda T. Vahdat  Rachel Layman  Denise A. Yardley  William Gradishar  Mohamad A. Salkeni  Anil Abraham Joy  Agustin A. Garcia  Patrick Ward  James Khatcheressian  Joseph Sparano  Gladys Rodriguez  Shande Tang  Ling Gao  Rita P. Dalal  John Kauh  Kathy Miller
Affiliation:1. Weill Cornell Breast Center, Weill Cornell Medicine, New York, New York, USA;2. Ohio State University, Columbus, Ohio, USA;3. Tennessee Oncology, Nashville, Tennessee, USA;4. Northwestern University Feinburg School of Medicine, Chicago, Illinois, USA;5. Mary Babb Randolph Cancer Center, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, West Virginia, USA;6. University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada;7. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA;8. Oncology Hematology Care Incorporated, Cincinnati, Ohio, USA;9. Virginia Cancer Institute, Richmond, Virginia, USA;10. Weiler Division, Montefiore Medical Center, Bronx, New York, USA;11. South Texas Oncology and Hematology, San Antonio, Texas, USA;12. Eli Lilly and Company, Indianapolis, Indiana, USA;13. Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, Indiana, USA
Abstract:
Keywords:Metastasis  Breast cancer  Monoclonal antibodies  Capecitabine  Drug resistance
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号